Incidence and risk of xerosis with targeted anticancer therapies

Valentine, Johannah; Belum, Viswanath Reddy; Duran, Juanita; Ciccolini, Kathryn; Schindler, Katja; Wu, Shenhong; Lacouture, Mario E.

doi:10.1016/j.jaad.2014.12.010

Cited by 43 publications

(28 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This works best when patients apply the ointment at night with cotton glove and sock occlusion Xerosis may be prevented by (1) bathing with bath oils or mild moisturizing soap, tepid water and following with regular moisturizing creams; (2) avoidance of extreme temperatures and direct sunlight. Management of mild/moderate xerosis employs (1) emollient creams that are packaged in a jar/tub without irritants; (2) occlusive emollients containing urea, colloidal oatmeal, and petroleum-based creams; (3) exfoliants for scaly or hyperkeratotic areas such as ammonium lactate 12% or lactic acid cream 12%; (4) urea cream (10–40%); (5) salicylic acid 6%; (6) zinc oxide (13–40%); and for severe, (7) medium- to high-potency steroid creams (Valentine et al, 2015). …”

Section: Xerosismentioning

confidence: 99%

Dermatologic Reactions to Targeted Therapy

Barton-Burke

Ciccolini

Mekas

et al. 2017

Nursing Clinics of North America

Self Cite

View full text Add to dashboard Cite

Synopsis Cancer treatments usually have side effects of bone marrow depression, mucositis, hair loss, and gastrointestinal issues. Rarely do we think of skin side effects until patients have been treated successfully with EGFRi as they commonly experienced skin reactions. Those skin reactions include papulopustular rash, hair changes, radiation dermatitis enhancement, pruritus, mucositis, xerosis, fissures, and paronychia. This paper discusses the common skin reactions seen when using EGFRi. This paper presents an overview of skin as the largest and important organ of the body including an overview of skin assessment, pathophysiology of the skin reactions, nursing care involved and introduction to the emerging cancer nursing specialty of oncodermatology.

show abstract

Section: Xerosismentioning

confidence: 99%

Dermatologic Reactions to Targeted Therapy

Barton-Burke

Ciccolini

Mekas

et al. 2017

Nursing Clinics of North America

Self Cite

View full text Add to dashboard Cite

show abstract

“…Whereas the incidence and risk of some of the targeted therapy-induced dermatologic AEs have been previously estimated [9, 10], that of dermatologic pigmentary AEs (dpAEs) is not known. The latter are of particular concern because of their persistence, resistance to therapy, and negative impact on psychosocial well-being and HRQoL.…”

Section: Introductionmentioning

confidence: 99%

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis

Dai

Belum

et al. 2017

Journal of the American Academy of Dermatology

Self Cite

View full text Add to dashboard Cite

Background The discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown. Objective To conduct a systematic review and meta-analysis of published clinical trials, and determine the incidence and risk of developing targeted therapy-induced pigmentary changes. Methods A comprehensive search was conducted to identify studies reporting targeted therapy-induced pigmentary changes. The incidence and relative risk were calculated. Case reports and series were reviewed to understand clinical characteristics. Results 8,052 patients from 36 clinical trials were included. The calculated overall incidences of targeted cancer therapy-induced all-grade pigmentary changes in the skin and hair were 17.7% (95% CI, 11.9–25.4) and 21.5% (95% CI, 14.9–30.1), respectively. The relative risk of all-grade pigmentary changes of skin and hair were 93.7 (95% CI: 5.86–1497.164) and 20.1 (95% CI: 8.35–48.248). Across 54 case reports/series (n=75 patients), EGFR and Bcr-abl inhibitors were the most common offending agents. Limitations Potential underreporting and variability in oncologists reporting these events. Conclusion There is a significant risk of developing pigmentary changes during treatment with targeted anticancer therapies. Appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life.

show abstract

“…Hydration is the main challenge in socio-aesthetics. Xeroderma often occurs during the decline stage of numerous medical conditions [20][21][22][23] . This situation has mainly been reported in patients with kidney failure and those who are on hemodialysis.…”

Section: Discussionmentioning

confidence: 99%